ArticleBrain, behavior, & immunity - health2026
A novel rat model of ovarian cancer and cisplatin chemotherapy-related cognitive impairment.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cancer-related cognitive impairment (CRCI) is a common, persistent complication of cancer and its treatment, yet its etiology in ovarian cancer remains poorly understood. Preclinical rat models integrating tumor burden and cognitive outcomes in ovarian cancer remain limited, and the contribution of tumor-associated processes has been insufficiently characterized. We developed an SKOV3.ip1 human ovarian cancer xenograft model of CRCI in female RNU rats, combined with a clinically relevant cisplatin regimen (4 cycles, 5 mg/kg, i.p.). Animals were randomly assigned to non-tumor (NT) or ovarian tumor-bearing (OvT) groups and to receive cisplatin (CDDP) or vehicle (VEH), resulting in four groups: NT + VEH, NT + CDDP, OvT + VEH, and OvT + CDDP. Anxiety-like behavior was assessed using the open field test, and cognitive function was evaluated using context object discrimination and novel object recognition tasks. Serum cytokine levels were measured in relation to behavioral outcomes. CDDP significantly impaired novel object recognition in non-tumor-bearing animals, but not in tumor-bearing animals which were impaired in object recognition regardless of treatment. NT + CDDP, OvT + VEH, and OvT + CDDP animals were significantly impaired relative to NT + VEH. Tumor implantation and cisplatin exposure were associated with alterations in systemic cytokine levels. Exploratory analyses identified IL-10 and C-reactive protein as candidate markers of reduced cognitive performance, although overall discriminative performance was modest. These findings demonstrate that the cognitive effects of chemotherapy depend on tumor status and underscore the importance of incorporating tumor-bearing conditions into preclinical CRCI models. Our model provides a translational platform to investigate tumor-treatment interactions and explore candidate inflammatory markers associated with cognitive outcomes in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.